Cargando…
Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
OBJECTIVE: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on‐the‐road driving in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA). METHODS: Eligible participants were aged 21–75 years with OSA and EDS (M...
Autores principales: | Vinckenbosch, Frederick, Asin, Jerryll, de Vries, Nicolaas, Vonk, Patty E., Donjacour, Claire E. H. M., Lammers, Gert Jan, Overeem, Sebastiaan, Janssen, Hennie, Wang, Grace, Chen, Dan, Carter, Lawrence P., Zhou, Kefei, Vermeeren, Annemiek, Ramaekers, Johannes G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788130/ https://www.ncbi.nlm.nih.gov/pubmed/35633275 http://dx.doi.org/10.1002/hup.2845 |
Ejemplares similares
-
Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions
por: Devine, Jaime K., et al.
Publicado: (2022) -
Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial
por: Vinckenbosch, Frederick, et al.
Publicado: (2022) -
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
por: Videnovic, Aleksandar, et al.
Publicado: (2021) -
Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment
por: Schweitzer, Paula K., et al.
Publicado: (2021) -
A randomized study of solriamfetol for excessive sleepiness in narcolepsy
por: Thorpy, Michael J., et al.
Publicado: (2019)